Advanced imaging detects early breast cancers not seen on Mammograms in dense breast tissue

Around 10% of women aged 50 to 70 in the UK have extremely dense breasts. This group is known to face a fourfold higher risk of developing breast cancer compared to women with low-density breast tissue.

WT default author logo
Women's Tabloid News Desk

New findings from a large-scale clinical trial published in The Lancet highlight the effectiveness of supplemental imaging techniques in detecting early-stage breast cancers in women with dense breast tissue, cases that standard mammograms often fail to identify.

The phase 3 randomized controlled trial, conducted across the UK, involved over 9,000 women with dense breasts and normal mammogram results. Participants were divided into three groups, each undergoing a different supplemental imaging technique: fast MRI, contrast-enhanced mammography, and ultrasound.

The results show a clear advantage for the more advanced methods. Cancer detection rates stood at 1.7% for fast MRI and 1.9% for contrast mammography. In comparison, ultrasound identified cancers in just 0.4% of participants. These figures point to a significant improvement in identifying cancers that may otherwise remain undiagnosed until more advanced stages.

Around 10% of women aged 50 to 70 in the UK have extremely dense breasts. This group is known to face a fourfold higher risk of developing breast cancer compared to women with low-density breast tissue. The structure of dense breast tissue can obscure tumours on standard mammograms, limiting their diagnostic value.

Although past studies have examined the role of MRI and ultrasound as supplementary tools, this is the first research effort to directly compare these techniques with contrast-enhanced mammography in women with negative mammograms but dense breast tissue.

While the study’s outcomes underline the potential life-saving role of these scans, researchers caution that more work is needed. Further investigation will determine whether early detection through these methods can reduce mortality, assess risks of overdiagnosis, and help weigh the cost-effectiveness of introducing such strategies into broader screening programs.

“In addition to the relevance for the UK’s breast cancer screening programme, this study has global implications for all countries where screening is undertaken for women with dense breast tissue,” said lead author Professor Fiona Gilbert of the University of Cambridge.

Share:

Related Insights

Liverpool Health Partners appoints Professor Louise Kenny as its first Chief Executive Officer

AIG Women’s Open prize fund reaches record USD 10 million for 50th anniversary

Sun Pharma to acquire Organon in US$ 11.75 billion deal

Zócalo Health secures $15 million in funding to expand care for Latino communities

Baroness Stuart reappointed as Royal Mint Advisory Committee chair for five months

GE HealthCare expands partnership to bring AI breast cancer screening to global markets

Donors pledge USD 800 million to tackle maternal and child mortality

ScreenPoint Medical secures 13.6 million euros to advance breast cancer AI technology